Skip to content

Undervalued German biotech play could be poised for lift off


This week we are adding a biotech stock to our longer term venture portfolio. This is a German-listed company, which specialises in T cell immunotherapies, for the treatment of cancer. Biotech can be a high risk sector to invest in, of course, as investors are heavily reliant on the regulatory approval of treatments in development.

We like this company because it looks cheap right now, with a PE value of 6.2 and shares are well off the high they achieved back in 2021, when they could be had for EUR 4.00. Now they have slipped to almost half that. Analysts are bullish however: two analysts are currently covering the biotech stock, and the consensus is for an improvement in sales of +151% versus 2021.

Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.

Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.

Free 28 day trial. Cancel anytime.

Log In or Sign Up to Armchair Trader+

Already a member? Log in here:

Not a member yet? Sign up for your free trial or check out the benefits of membership.

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.

Looking for great investing ideas? Sign up to our free newsletter.

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top